McHade LAST VERIFIED: August 7, 2026

McHade, presented as McHade Pharmaceuticals, is a US-based specialty pharmaceutical distributor focused on the US and Canada. Its services include comparator and reference-listed-drug sourcing, clinical trial supplies, pharmaceutical 3PL and cold-chain warehousing, named patient programs, and US depot or white-label distribution for international pharma companies. No founding year is published. The company claims to supply 50 countries, a 90 percent fulfillment rate, and delivery of 98 percent of shipments within 48 hours — all self-reported figures that cannot be confirmed from the site. A toll-free line is published for initial contact with prospective partners.

This is a consultation-driven B2B operation, not a catalog storefront. Engagement begins by booking a consultation; there is no ecommerce ordering of any kind. Commercial terms such as minimum order quantity and minimum order value are project-based and not published on the site. Logistics are temperature-controlled and cold-chain capable, with the company claiming 98 percent of shipments delivered within 48 hours. The site does not state payment methods, and dropshipping is not applicable to this model. Buyers should expect contract-by-contract negotiation covering scope, pricing, and compliance, with nothing standardized or published in advance.

McHade serves a genuinely specialized niche — comparator sourcing and clinical trial logistics — and its service scope reads plausibly for that market. The caveats are significant, though. The site displays FDA, DEA, EMA, Health Canada, WHO, and MHRA logos, but these are regulatory bodies, not certifications, and no license numbers or verifiable accreditations are shown, so the implied compliance is unproven. Every performance statistic is self-reported. Given that pharmaceutical sourcing demands strict licensure, prospective partners should request license documentation, references, and audit evidence directly before engaging, treating the marketing claims as a starting point rather than proof.